Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study
Open Access
- 31 July 2013
- journal article
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 167
Abstract
Some parenteral iron therapies have been found to be associated with hypophosphatemia. The mechanism of the decrease in serum phosphate is unknown. The aim of this study is to examine the effect of IV ferric carboxymaltose(FCM) on phosphate metabolism and FGF23 levels in patients with chronic kidney disease(CKD).Keywords
This publication has 48 references indexed in Scilit:
- Understanding Iron: Promoting Its Safe Use in Patients With Chronic Kidney Failure Treated by HemodialysisAmerican Journal of Kidney Diseases, 2013
- Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI StudyThe American Journal of Medicine, 2012
- Intact fibroblast growth factor 23 and fragments in plasma from Gambian childrenOsteoporosis International, 2012
- A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implicationsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Hypophosphatemia induced by intravenous administration of saccharated ferric oxideBone, 2009
- Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trialAmerican Journal of Obstetrics and Gynecology, 2008
- Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patientsBone, 2008
- Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantationBone Marrow Transplantation, 2000
- Cefotetan‐induced hemolytic anemia causing severe hypophosphatemiaAmerican Journal of Hematology, 1994
- Dietary protein alters tubular iron accumulation after partial nephrectomyKidney International, 1994